)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
X4 Pharmaceuticals
X4 Pharmaceuticals (XFOR) investor relations material
X4 Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Q3 2026 revenue rose to $2.9M from $1.8M YoY, driven by U.S. product sales; net loss narrowed to $20.2M from $29.8M.
4WARD enrollment is on track to reach 126 participants in Q4 2026 after FDA feedback supported the reduced target; topline data are expected in Q1 2028.
Cash, cash equivalents and marketable securities totaled $187.7M at September 30, 2026, with runway expected into Q1 2029.
Financial highlights
Q3 product revenue was $2.8M versus $1.6M YoY; 9M product revenue was $7.6M versus $4.3M, reflecting more patients prescribed XOLREMDI.
9M total revenue was $14.4M versus $32.5M YoY; 2025 included $27.6M from the Norgine license, while 2026 included a $5.5M license milestone.
Q3 net loss was $20.2M, or $0.16 per share, versus $29.8M, or $0.69 per share; 9M net loss was $56.6M, or $0.45 per share, versus $55.3M, or $2.87 per share.
Q3 operating loss was $20.0M versus $27.5M; 9M operating loss was $56.7M versus $63.2M.
Q3 R&D and G&A expenses were $13.3M and $9.0M; 9M expenses were $43.9M and $24.5M, respectively, both lower YoY.
Outlook and guidance
4WARD enrollment of 126 participants is expected to finish in Q4 2026; topline data are expected in Q1 2028, supporting potential FDA approval in late 2028 or early 2029.
The Phase 2b 4STEPS trial plans to enroll ~25 PCN patients beginning in Q1 2027, with topline results expected in Q1 2028.
Cash runway is expected into Q1 2029; additional term-loan advances remain subject to lender discretion and covenant compliance.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from X4 Pharmaceuticals
- Mavorixafor’s PCN opportunity pairs a ~15,000-patient base with Q1 2028 readouts.XFOR
Investor Day 2026 - 4WARD topline data are expected in H1 2028, backed by Phase 2 evidence of ANC gains and reduced G-CSF use.XFORCorporate presentation
- Phase III enrollment nears completion, with launch targeted for late 2028 or early 2029.XFORWells Fargo 21st Annual Healthcare Conference
- Q2 2026 revenue was $8.8M, net loss improved, and cash runway extends into 2029.XFORQ2 2026
- XOLREMDI launch gains traction as Phase 3 CN trial advances and global expansion plans progress.XFORStifel 2024 Healthcare Conference
- Advancing an oral therapy for chronic neutropenia with pivotal data in 2027 and FDA approval targeted for 2028.XFORJefferies Global Healthcare Conference 2026
- Up to $75M in at-the-market stock sales will fund clinical trials amid significant dilution risk.XFORRegistration filing
- Q2 net income hit $90.8M on $105M PRV sale and XOLREMDI U.S. launch.XFORQ2 2024
- Mavorixafor durably increased ANC and showed good tolerability in chronic neutropenia Phase 2.XFORStudy Update
Next X4 Pharmaceuticals earnings date
3rd Annual Guggenheim Healthcare Innovation Conference10 Nov, 2026
X4 Pharmaceuticals
Next X4 Pharmaceuticals earnings date
3rd Annual Guggenheim Healthcare Innovation Conference10 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
X4 Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for rare diseases, particularly those involving immune system dysfunctions. The company leverages its expertise in small-molecule therapeutics to address conditions associated with abnormal white blood cell activity. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.